MiniMed Group, Inc. Common Stock
NASDAQ:MMEDMedical - Care Facilities
+$0.40 today
- Market cap
- $4.78B
- Beta
- -3.63
- P/E (TTM)
- -14.2
- EPS (TTM)
- -$1.91
Volume 4.70M
Average 0.95M
MMED Accounts Receivables
Cash effect of the change in amounts owed by customers; growing receivables consume cash.
MiniMed Group, Inc. Common StockNASDAQ: MMED
Accounts Receivables · Q1 FY2026 · quarter ended Jul 2026
Accounts receivables of -$148M in Q1 FY2026
Q1 FY2026 accounts receivables was -$148M. Trailing-twelve-month accounts receivables was -$681M. Over 3 fiscal years it compounded at +97.3% a year.
Context
- Accounts receivables amounted to 17.3% of revenue in FY2025, up 14.9 pp from a year earlier.
- Accounts receivables grew in size in 2 of the last 3 fiscal years.
- FY2025 was the largest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly accounts receivables holds near -$148M or moves back toward the trailing-twelve-month quarterly average of -$170.25M.
Sources:Cash FlowText generated from reported figures; not investment advice.
Accounts Receivables history
USD · from the cash flow
- Latest · FY2025
- (538M) USD
- Year-over-year change
- -715.2%
| Period | Period end | Accounts Receivables | YoY change |
|---|---|---|---|
| FY2025 | 2026-04-24 | (538M) | -715.2% |
| FY2024 | 2025-04-30 | (66M) | +37.1% |
| FY2023 | 2024-04-30 | (105M) | -50.0% |
| FY2022 | 2023-04-30 | (70M) | — |
Accounts Receivables vs competitors
How MMED compares with its peers on the latest reported figures
- MMED's LTM Jul 2026 accounts receivables of $681M is the largest of the 7 companies compared; the peer median is $17.36M.
- Accounts receivables amounts to 21.1% of revenue for MMED, versus a peer median of 2.9%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
MMEDMiniMed Group, Inc. Common Stock | LTM Jul 2026 | $681M | — | +97.3% | 21.1% |
| LTM Jul 2026 | $264M | +3.5% | -29.7% | 0.7% | |
| LTM Jun 2026 | $107.5M | +57.9% | +39.4% | 3.5% | |
| LTM Jun 2026 | $84.1M | +121.2% | +0.3% | 1.7% | |
| LTM Mar 2026 | $23.29M | -43.8% | +93.6% | 2.3% | |
| LTM Mar 2026 | $11.43M | +537.2% | +141.9% | 28.1% | |
| LTM Mar 2026 | $6.73M | +143.5% | — | 6.1% | |
MMEDVMiniMed Group, Inc. | — | — | — | — | — |
| Peer median (excluding MMED) | $17.36M | +89.5% | +39.4% | 2.9% | |
Competitors are the stored peer set for MMED. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2022 Apr 2023 | FY2023 Apr 2024 | FY2024 Apr 2025 | FY2025 Apr 2026 |
|---|---|---|---|---|
| Net Income | (92M) | (107M) | (198M) | (317M) |
| Depreciation & Amortization | 115M | 129M | 143M | 156M |
| Deferred Income Tax | (11M) | 3M | (2M) | (54M) |
| Stock-Based Compensation | 35M | 38M | 41M | 46M |
| Change in Working Capital | (90M) | (74M) | 122M | (166M) |
| Accounts Receivables | (70M) | (105M) | (66M) | (538M) |
| Inventory | (28M) | 5M | (19M) | (29M) |
| Accounts Payables | 14M | (4M) | 191M | 41M |
| Other Working Capital | (6M) | 30M | 16M | 360M |
| Other Non-Cash Items | 37M | 52M | 34M | 138M |
| Operating Cash Flow | (6M) | 41M | 140M | (197M) |
| Capital Expenditures | (167M) | (148M) | (193M) | (223M) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 |
| Purchases of Investments | (13M) | (5M) | 0 | 0 |
| Sales of Investments | 0 | 11M | 0 | 0 |
| Other Investing Activities | 0 | (15M) | 0 | (10M) |
| Investing Cash Flow | (180M) | (157M) | (193M) | (233M) |
| Debt Repayment | 0 | 0 | 0 | 0 |
| Common Stock Issued | 0 | 0 | 0 | 538M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 |
| Other Financing Activities | 185M | 112M | 10M | 178M |
| Financing Cash Flow | 185M | 112M | 10M | 716M |
| Effect of Forex Changes | 0 | 0 | 0 | 1M |
| Net Change in Cash | (2M) | (4M) | (43M) | 287M |
| Free Cash Flow | (173M) | (107M) | (53M) | (420M) |
MiniMed Group, Inc. Common Stock
NASDAQ:MMED
Intrinsic Alpha fair value
Locked
Current Price
$16.99
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.